EUs zögerlicher Beginn mit Covid-19 Impfungen (1)
February 3, 2021 -
Die zögerliche Annäherung an den Beginn der Covid-19 Impfungen hat seine Wurzeln in den Zeiten, zu denen die Aufträge an die pharmazeutischen Firmen erteilt wurden und später der langwierige Zulassungsprozess durch die Europäischen Medikamenten Aufsichtsbehörde (EMA).
The European Union's Covid-19 vaccination programme is struggling to get its hands on enough vaccine – trailing countries like Israel, the UK and United States. Worryingly, there seems no sign of the vaccination rate increasing anytime soon, unlike the UK, where rates have increased markedly in recent days.
A key failure is that the EU simply ordered too few vaccines too late. For example, it was too slow to order the Pfizer/BioNTech vaccine, even after it became the frontrunner, and member states hesitated to ask the EU to order more.
Drug purchases were further delayed by disagreements over liability in case of negative side-effects on health from the vaccines, with the EU pushing for it to rest with pharmaceutical companies. This led to the rejection of early emergency authorisations as many EU member states were averse to such risks. European anti-vaccination movements may have compounded the pressures on politicians too.
The EU, with a population of nearly 450 million people, also found its funding wanting. Last year, it allocated €3.79 billion ($4.56 billion) for advance purchase agreements. By comparison, the U.S., with a lesser population of under 330 million people, pledged $18 billion.
The EU also chose to bargain with Big Pharma to achieve lower purchases prices, as if it had plenty of time on its hands, whereas other nations acted to expedite huge orders.
Further adding to the disarray is the EU's slow speed to develop a strategy to increase production. More factories could have been mobilised as soon as possible to increase the total supply of vaccines, instead of waiting until this year to do so.
A recent furious spat with the UK has fuelled debate that the makers of the AstraZeneca vaccine may be breaching the terms of its contract with the EU, by not supplying enough vaccines to the bloc while maintaining good deliveries to the UK. But as the AstraZeneca CEO points out, the UK signed its contract three months before the EU and the UK factory also started operating earlier, increasing its capacity to supply.
- Why has the EU been so slow to roll out a Covid vaccination programme? (The Guardian)
- Commission President Ursula von der Leyen seeking to duck responsibility (Spiegel International)
- EU vaccines blame game intensifies (Financial Times)
- Coronavirus vaccines strategy (European Commission)
- Covid vaccines: What has UK ordered so far as new Novavax jab found to be 89% effective? (ITV)